President Trump's deadline for drug price concessions has come and gone. And so far the pharmaceutical industry's expanding list of commitments has included everything but what Trump really wants.
Why it matters: Not committing to lower U.S. drug prices will test how much Trump is willing to throw behind his threat of regulations.
Driving the news: PhRMA, the drugmakers' top trade group, yesterday announced several actions it's taking or has already taken to answer Trump's "call to put America first," as CEO Stephen Ubl put it in a press release.
It highlighted the $500 billion that member companies have committed to spending on U.S.-based infrastructure, financial assistance programs they're providing to patients and the launch of a new website that will connect patients with drug companies' direct-purchasing programs.
Some companies, including AstraZeneca and Bristol Myers Squibb, have already announced that they'll let patients buy certain drugs directly, cutting out the middlemen that the drug industry blames for high patient costs.
Print Page
Email to a Friend